STAT Inhibitors Drug Pipeline Markets Research 2022: Insights About 60+ Companies and 60+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “STAT Inhibitors – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

STAT Inhibitors: Overview

Signal Transducer and Activator of Transcription (STAT) proteins are a family of cytoplasmic transcription factors consisting of 7 members, STAT1 to STAT6, including STAT5a and STAT5b. STAT proteins are thought to be ideal targets for anti-cancer therapy since cancer cells are more dependent on the STAT activity than their normal counterparts. Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides.

STAT Inhibitors Emerging Drugs Chapters

This segment of the STAT Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

STAT Inhibitors Emerging Drugs

SHR0302: Jiangsu Hengrui Medicine

SHR0302 is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. It inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has an anti-proliferative and anti-inflammatory effect. It is currently in phase III stage of development.

OPB-111077: Otsuka Pharmaceutica

OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy.

Niclosamide intramuscular depot: Daewoong Pharmaceutical

Niclosamide intramuscular depot is being developed by Daewoong Pharmaceutical for the treatment of COVID 2019 infections. It is currently in phase I stage of development.

STAT Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different STAT Inhibitors drugs segregated based on following parameters that define the scope of the report.

Major Players in STAT Inhibitors

There are approx. 60+ key companies which are developing the therapies based on STAT Inhibitors. The companies which have their drug candidate based on STAT Inhibitors in the most advanced stage, i.e. phase II/III include Jiangsu Hengrui Medicine and others

STAT Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses STAT Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging STAT Inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Reistone’s oral JAK1 inhibitor, SHR0302, is a China developed molecule licensed-in from Jiangsu Hengrui Medicine Co Ltd (Hengrui).

STAT Inhibitors Report Insights

• STAT Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

STAT Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Players

• Singh Biotechnology
• AndroScience Corporation
• Wyeth
• Astellas
• Dolthera
• Jiangsu Hengrui Medicine
• Otsuka Pharmaceutica
• Daewoong Pharmaceutical

Key Products

• SBT 101
• ASC ST.Z1

Research Programme: STAT3 transcription factor inhibitors

Research Programme: STAT6 inhibitors

• AVT 02
• SHR0302
• OPB-111077
• Niclosamide intramuscular depot

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/8srwzf

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900